IntelGenx to Report First Quarter 2017 Financial Results on May 11, 2017 - Conference Call to Follow

May 04, 2017

SAINT LAURENT, QUEBEC -- (Marketwired) -- 05/04/17 -- IntelGenx Technologies Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced that it will release its first quarter 2017 financial results after market close on May 11, 2017.

An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:

Date: Thursday, May 11, 2017

Time: 4:30 p.m. ET

Conference dial-in: (877) 201-0168

International dial-in: (647) 788-4901

Conference ID: 18899915

Webcast Registration: Click here

Following the live call, a replay will be available on the Company's website,, under "Investor Relations".

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

Investor Relations
Stephen Kilmer
(514) 331-7440 ext. 232
IntelGenx Technologies Corp.
Andre Godin, CPA, CA
Executive Vice-President and CFO
(514) 331-7440 ext. 203

Source: IntelGenx Technologies Corp.